U.S. flag An official website of the United States government
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Eliminating Youth Electronic Cigarette and Other Tobacco Product Use: The Role for Drug Therapies Public Hearing - 01/18/2019 - 01/18/2019
  1. FDA Meetings, Conferences and Workshops

Public Hearing

Event Title
Eliminating Youth Electronic Cigarette and Other Tobacco Product Use: The Role for Drug Therapies Public Hearing
January 18, 2019


Date:
January 18, 2019
Time:
09:00 AM - 03:15 PM EST
Location:
Event Location
White Oak Campus: The Great Room
Conference Center

10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
United States


Organized By:

The Food and Drug Administration (FDA or the Agency) is announcing a public hearing to discuss the effort to eliminate youth electronic cigarette (e-cigarette) use as well as other tobacco product use, with a focus on the potential role of drug therapies to support cessation and the issues impacting the development of such therapies.

Meeting Information

View Recorded Webcast

Part 1: https://collaboration.fda.gov/pny4rpisx50p/
Part 2: https://collaboration.fda.gov/p8j0g3w3ox16/
Part 3: https://collaboration.fda.gov/pqr29s4z8btf/

Registration

Please use Register to attend the event in-person or via webcast at Eventbrite to register to (1) Attend In-Person (2) Attend In-Person and make a presentation (3) Attend In-Person and make public comment (4) Attend via webcast. Please read ticket descriptions in Eventbrite to make the appropriate selection.

If you need special accommodations due to a disability, please contact Theresa Wells at 703-380-3900 or theresa.wells@fda.hhs.gov by January 11, 2019.

Submitting Comments

Regardless of attendance at the public meeting, you can submit electronic or written comments to the public docket by February 1, 2019 (extended from the original January 2, 2018 deadline). Submit electronic comments to Regulations.gov. Submit written comments to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

All comments must be identified with the docket number FDA-2018-N-3952. The FDA may post, without change, all comments received to Regulations.gov, including any personal information provided.

Questions

If you have questions about registering for the meeting, contact Theresa Wells, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, phone: 703-380-3900 or email theresa.wells@fda.hhs.gov.